CD38 and plasma cell myeloma: Histone deacetylase (HDAC) inhibitors (Panobinostat, Ricolinostat) upregulate CD38 RNA levels and CD38 surface expression on multiple myeloma cells [55], thus disrupting latency of the malignant cells.